Related Experiment Video

Updated: Jun 15, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

mTOR inhibitor-associated dermatologic and mucosal problems

Josep M Campistol1, Johan W de Fijter, Stuart M Flechner

  • 1Department of Urology and Nephrology, Hospital Clinic i Provincial, Barcelona, Spain.

Clinical Transplantation
|March 19, 2010
PubMed

Insights

Mammalian target of rapamycin (mTOR) inhibitor use can cause skin and mucosal issues. Clinicians should be aware of these potential adverse events for effective patient management and treatment.

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Mammalian target of rapamycin (mTOR) inhibitors are crucial in treating various conditions.
  • Adverse events, particularly dermatologic and mucosal complications, are common with mTOR inhibitor therapy.
  • These side effects range in severity and onset time.

Purpose of the Study:

  • To examine the dermatologic and mucosal problems associated with mTOR inhibitor use.
  • To review existing literature on these adverse events.
  • To provide insights into the management and treatment of these complications.

Main Methods:

  • Literature review of studies on mTOR inhibitor-associated adverse events.
  • Analysis of clinical manifestations of dermatologic and mucosal problems.
  • Compilation of personal experiences in managing these side effects.

Main Results:

  • Sirolimus and other mTOR inhibitors frequently cause a spectrum of skin and mucosal adverse events.
  • These complications can vary significantly in presentation and timing post-initiation.
  • Effective management strategies are crucial for patient adherence and outcomes.

Conclusions:

  • Awareness of mTOR inhibitor-induced dermatologic and mucosal issues is essential for healthcare providers.
  • Timely recognition and appropriate interventions can mitigate the impact of these adverse events.
  • Further research into optimal management protocols is warranted.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.